Cabaletta Bio, Inc.
Cabaletta Bio, Inc. (CABA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
caba · stock forecast · 12 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 12 Wall Street analysts in the past 3 months
Buy
12 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$32.00
Consensus
$16.33
+410.3% upside
Low
$3.00
Median: $14 · Last Close: $3.20
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$16.33
410.3% upside
High Target
$32
900.0%
Low Target
$3
-6.3%
Current Price
$3.20
as of today
Based on analyst price targets, the CABA stock price prediction for the next 12 months ranges from $3 to $32. The consensus CABA price forecast of $16.33 implies 410.3% upside from the current price of $3.20.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $3.13 | ↓ 2.33% |
1-day model range: $3.08–$3.17. Peak: $3.17 (-2.33%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CABA · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-15 | Wells Fargo | Maintains | Equal Weight→Equal Weight |
| 2026-05-04 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2026-03-24 | Guggenheim | Maintains | Buy→Buy |
| 2026-03-24 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2025-10-31 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2025-10-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-05 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2025-08-14 | Citigroup | Maintains | Buy→Buy |
| 2025-08-08 | Guggenheim | Maintains | Buy→Buy |
| 2025-08-08 | Wells Fargo | Maintains | Equal Weight→Equal Weight |
Wall Street analysts have recently issued updated ratings on Cabaletta Bio, Inc. (CABA) stock. Of the recent 76 rating actions, 1 were upgrades and 3 were downgrades. 12 analysts currently cover CABA.
Analyst Recommendation Trends
CABA analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$3M
↓ 96.1% YoY
Revenue Next Year
$1M
↓ 71.5% YoY
EPS This Year
$-1.38
EPS Next Year
$-1.27
↓ 8.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast CABA EPS of $-1.38 for the current fiscal year, based on estimates from 5 analysts. The CABA revenue forecast is $3M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CABA stock forecast is supported by two independent data sources: analyst consensus ratings from 12 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CABA price target is $16.33 (+410.3% upside), with an analyst consensus of Buy.
The CABA short-term stock prediction for tomorrow is $3.13 (-2.33%).
Cabaletta Bio, Inc. trades on NASDAQ under the ticker CABA. The CABA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 83% of covering analysts.
Frequently asked questions
CABA forecast · 8 questionsAccording to 12 Wall Street analysts, the average 12-month CABA price target is $16.33, with a high forecast of $32.00 and a low of $3.00. The median price target is shown in the chart above when available. This implies +410.3% potential upside from the current price of $3.20.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.